NOMAC-E2 shows a better contraceptive effectiveness than LNG combined oral contraceptives in women under 25: real-world PRO-E2 study

Figures & data

Table 1. Selected baseline characteristics of women under 25 years by user cohort.

	NOMAC-E2	COCLNG	Total
Number (%) of women	12,829 (42.9)	17,095 (57.1)	29,924 (100)
WY (%)	12,905 (28.7)	18,881 (42.1)	44,893** (100)
Age (years)*
Mean	21.0	20.5	20.7
SD	2.57	2.61	2.60
User status, n (%)
Starter	9,529 (74.3)	13,041 (76.3)	22,570 (75.4)
Restarter	3,300 (25.7)	4,054 (23.7)	7,354 (24.6)
Weight (kg)
Mean (SD)	59.8 (11.02)	59.7 (11.31)	59.8 (11.18)
BMI (kg/m^2)
Mean (SD)	22.0 (3.80)	22.1 (3.89)	22.0 (3.85)
Current smoker, n (%)	2,932 (22.9)	4,284 (25.1)	7,216 (24.1)
Heavy smoker (>15 cigarettes per day)	233 (1.8)	359 (2.1)	592 (2.0)
Ever been pregnant (gravidity), n (%)	2,296 (17.9)	3,278 (19.2)	5,574 (18.6)
Thereof at least one live birth (parity), n (%)	1,336 (58.2)	2,145 (65.4)	3,481 (62.5)
Reasons for COC prescription at study entry, n (%)
Contraception only	6,557 (51.1)	9,107 (53.3)	15,664 (52.3)
Contraceptive and/or non-contraceptive reasons	6,063 (47.3)	7,788 (45.6)	13,851 (46.3)
Thereof reason acne, n (%)	1,006 (16.6)	985 (12.6)	1,991 (14.4)
Non-contraceptive reasons only	1,247 (9.7)	1,500 (8.8)	2,747 (9.2)
Education level, n (%)
Less than university entrance level	2,916 (22.7)	5,020 (29.4)	7,936 (26.5)
University entrance level	6,615 (51.6)	7,778 (45.5)	14,393 (48.1)
More than university entrance level	2,883 (22.5)	3,570 (20.9)	6,453 (21.6)
Depression requiring treatment, n (%)	220 (1.7)	373 (2.2)	593 (2.0)

BMI: Body mass index; COC_LNG: Levonorgestrel-containing combined oral contraceptive; NOMAC-E2: Nomegestrol acetate and 17β-estradiol; SD: Standard deviation; WY: Women-years.

* Data privacy regulations in Germany restricted the capture of date of birth information to the year of birth only. The day and month of birth for patients in that country were set to 1st July.

** Describes WY from the whole study population, including women who stopped using hormonal contraceptives (ex-use) or switched to other contraceptives during the follow-up period.

Figure 1. Contraceptive failure rates by user cohort; HR_crude: crude hazard ratio; HR_adj: adjusted hazard ratio.

Figure 2. Changes from baseline to 12-months follow-up in weight (a), mood score (b), and acne score (c) by user cohort; (–) indicates weight loss and mood/acne score worsening, respectively; (+) indicates weight gain and mood/acne score improvement, respectively.